Dexcom (DXCM) Capital Expenditures Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Zimmer Biomet Holdings | 16.17 Bn | 15.75 Bn | 1.51 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.13% |
| Dec 31, 2025 | 11.10% |
| Sep 30, 2025 | 11.17% |
| Jun 30, 2025 | 10.09% |
| Mar 31, 2025 | 21.25% |
| Dec 31, 2024 | 23.09% |
| Sep 30, 2024 | 17.48% |
| Jun 30, 2024 | 7.10% |
| Mar 31, 2024 | 7.68% |
| Dec 31, 2023 | 24.29% |
| Sep 30, 2023 | 16.19% |
| Jun 30, 2023 | 41.78% |
| Mar 31, 2023 | 37.32% |
| Dec 31, 2022 | 29.26% |
| Sep 30, 2022 | 51.63% |
| Jun 30, 2022 | 50.12% |
| Mar 31, 2022 | 34.71% |
| Dec 31, 2021 | 35.44% |
| Sep 30, 2021 | 46.35% |
| Jun 30, 2021 | 57.33% |
| Mar 31, 2021 | 54.03% |
| Dec 31, 2020 | 39.00% |
| Sep 30, 2020 | 44.98% |
| Jun 30, 2020 | 56.00% |
| Mar 31, 2020 | 32.93% |
| Dec 31, 2019 | 57.16% |
| Sep 30, 2019 | 68.12% |
| Jun 30, 2019 | 63.61% |
| Mar 31, 2019 | 58.73% |
| Dec 31, 2018 | 50.40% |
| Sep 30, 2018 | 61.00% |
| Jun 30, 2018 | 38.79% |
| Mar 31, 2018 | 61.33% |
| Dec 31, 2017 | 65.91% |
| Sep 30, 2017 | 36.02% |
| Jun 30, 2017 | 32.85% |
| Mar 31, 2017 | 58.35% |
| Dec 31, 2016 | 37.79% |
| Sep 30, 2016 | 60.62% |
| Jun 30, 2016 | 55.36% |
| Mar 31, 2016 | 45.05% |
| Dec 31, 2015 | 37.43% |
| Sep 30, 2015 | 28.73% |